NUMA1 and breast cancer: The utility of the urinary NMP22 test for NMIBC diagnosis and surveillance has been demonstrated, with sensitivity and specificity values for detection of primary or recurrent BC ranging from 49.5% to 55.7%, and from 85.7% to 87.3%, respectively [18], [19], [20].